- Home
- LPTX vs STEM Comparison
LPTX vs STEM Comparison
Compare LPTX & STEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- STEM
- Stock Information
- Founded
- LPTX 2011
- STEM 2009
- Country
- LPTX United States
- STEM United States
- Employees
- LPTX N/A
- STEM N/A
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- STEM Computer Software: Prepackaged Software
- Sector
- LPTX Health Care
- STEM Technology
- Exchange
- LPTX Nasdaq
- STEM Nasdaq
- Market Cap
- LPTX 119.6M
- STEM 135.7M
- IPO Year
- LPTX N/A
- STEM N/A
- Fundamental
- Price
- LPTX $2.55
- STEM $0.70
- Analyst Decision
- LPTX Strong Buy
- STEM Hold
- Analyst Count
- LPTX 3
- STEM 8
- Target Price
- LPTX $7.50
- STEM $1.38
- AVG Volume (30 Days)
- LPTX 335.2K
- STEM 25.4M
- Earning Date
- LPTX 11-13-2024
- STEM 02-26-2025
- Dividend Yield
- LPTX N/A
- STEM N/A
- EPS Growth
- LPTX N/A
- STEM N/A
- EPS
- LPTX N/A
- STEM N/A
- Revenue
- LPTX N/A
- STEM $256,183,000.00
- Revenue This Year
- LPTX N/A
- STEM N/A
- Revenue Next Year
- LPTX N/A
- STEM $130.56
- P/E Ratio
- LPTX N/A
- STEM N/A
- Revenue Growth
- LPTX N/A
- STEM N/A
- 52 Week Low
- LPTX $1.68
- STEM $0.30
- 52 Week High
- LPTX $4.79
- STEM $3.58
- Technical
- Relative Strength Index (RSI)
- LPTX 37.35
- STEM 51.79
- Support Level
- LPTX $2.88
- STEM $0.57
- Resistance Level
- LPTX $3.27
- STEM $0.92
- Average True Range (ATR)
- LPTX 0.28
- STEM 0.23
- MACD
- LPTX -0.06
- STEM -0.02
- Stochastic Oscillator
- LPTX 12.71
- STEM 24.90
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .
About STEM Stem Inc.
Stem Inc is a provider of energy storage systems. The company bundles third-party hardware with its proprietary Athena software to provide customers a turnkey solution. Stem sells its solutions to commercial and industrial customers as well as independent power producers and renewable developers. Its solutions help customers maximize renewable energy generation and help build a cleaner and more resilient grid. The Company operates as one operating segment that is focused exclusively on innovative technology services that transform the way energy is distributed and consumed.